Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy

Barbara Cipriani, Arthur Fridman, Claus Bendtsen, Shridar Dharmapuri, Carmela Mennuni, Irene Pak, Giuseppe Mesiti, Guido Forni, Paolo Monaci, Ansu Bagchi, Gennaro Ciliberto, Nicola La Monica, Elisa Scarselli

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of genetic vaccination with rat ErbB2 antigen in a therapeutic setting for the BALB-neuT mouse model of mammary carcinoma and to establish immunological correlates with vaccine efficacy. To define an early therapeutic setting we performed imaging studies of mouse mammary glands with a high-frequency ultrasound system that allowed the diagnosis of tumor lesions before they become palpable, starting from week 13 after mouse births. An intensive immunization protocol of vaccination was implemented at this stage, consisting of four weekly DNA injections with electroporation followed by two injections of adenovirus carrying the codon usage-optimized cDNA encoding the extracellular-transmembrane domain of rat ErbB2. Immunological parameters were monitored in each individual mouse by analyzing peripheral blood leukocytes. The appearance of the first palpable tumor in vaccinated mice was delayed and there was a statistically significant time gap before additional masses developed, indicating disease stabilization. As a result of the immunization, antibodies and CD8+ T cells to rat ErbB2 were detected and the amplitude of elicited responses correlated with the efficacy of vaccination. Moreover, the vaccination regimen specifically halted the rise in circulating myeloid suppressor cells (MSCs). All three parameters, that is, CD8+ T cells, antibodies to rat ErbB2, and circulating MSCs, measured at the end of vaccination could be used as predictive biomarkers for future tumor development. This study emphasizes the potential of genetic vaccines for the therapeutic treatment of malignancies and suggests possible predictive biomarkers to be further validated in the clinic for the follow-up of vaccinated cancer patients.

Original languageEnglish
Pages (from-to)670-680
Number of pages11
JournalHuman Gene Therapy
Volume19
Issue number7
DOIs
Publication statusPublished - Jul 1 2008

Fingerprint

Disease Progression
Vaccination
Vaccines
Myeloid Cells
Immunization
Neoplasms
T-Lymphocytes
Therapeutics
Injections
Electroporation
Antibodies
Human Mammary Glands
Tumor Biomarkers
Adenoviridae
Codon
Leukocytes
Complementary DNA
Biomarkers
Parturition
Breast Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Therapeutic vaccination halts disease progression in BALB-neuT mice : The amplitude of elicited immune response is predictive of vaccine efficacy. / Cipriani, Barbara; Fridman, Arthur; Bendtsen, Claus; Dharmapuri, Shridar; Mennuni, Carmela; Pak, Irene; Mesiti, Giuseppe; Forni, Guido; Monaci, Paolo; Bagchi, Ansu; Ciliberto, Gennaro; Monica, Nicola La; Scarselli, Elisa.

In: Human Gene Therapy, Vol. 19, No. 7, 01.07.2008, p. 670-680.

Research output: Contribution to journalArticle

Cipriani, B, Fridman, A, Bendtsen, C, Dharmapuri, S, Mennuni, C, Pak, I, Mesiti, G, Forni, G, Monaci, P, Bagchi, A, Ciliberto, G, Monica, NL & Scarselli, E 2008, 'Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy', Human Gene Therapy, vol. 19, no. 7, pp. 670-680. https://doi.org/10.1089/hum.2007.127
Cipriani, Barbara ; Fridman, Arthur ; Bendtsen, Claus ; Dharmapuri, Shridar ; Mennuni, Carmela ; Pak, Irene ; Mesiti, Giuseppe ; Forni, Guido ; Monaci, Paolo ; Bagchi, Ansu ; Ciliberto, Gennaro ; Monica, Nicola La ; Scarselli, Elisa. / Therapeutic vaccination halts disease progression in BALB-neuT mice : The amplitude of elicited immune response is predictive of vaccine efficacy. In: Human Gene Therapy. 2008 ; Vol. 19, No. 7. pp. 670-680.
@article{645478e54beb48febf77fb012f727f41,
title = "Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy",
abstract = "The aim of this study was to evaluate the efficacy of genetic vaccination with rat ErbB2 antigen in a therapeutic setting for the BALB-neuT mouse model of mammary carcinoma and to establish immunological correlates with vaccine efficacy. To define an early therapeutic setting we performed imaging studies of mouse mammary glands with a high-frequency ultrasound system that allowed the diagnosis of tumor lesions before they become palpable, starting from week 13 after mouse births. An intensive immunization protocol of vaccination was implemented at this stage, consisting of four weekly DNA injections with electroporation followed by two injections of adenovirus carrying the codon usage-optimized cDNA encoding the extracellular-transmembrane domain of rat ErbB2. Immunological parameters were monitored in each individual mouse by analyzing peripheral blood leukocytes. The appearance of the first palpable tumor in vaccinated mice was delayed and there was a statistically significant time gap before additional masses developed, indicating disease stabilization. As a result of the immunization, antibodies and CD8+ T cells to rat ErbB2 were detected and the amplitude of elicited responses correlated with the efficacy of vaccination. Moreover, the vaccination regimen specifically halted the rise in circulating myeloid suppressor cells (MSCs). All three parameters, that is, CD8+ T cells, antibodies to rat ErbB2, and circulating MSCs, measured at the end of vaccination could be used as predictive biomarkers for future tumor development. This study emphasizes the potential of genetic vaccines for the therapeutic treatment of malignancies and suggests possible predictive biomarkers to be further validated in the clinic for the follow-up of vaccinated cancer patients.",
author = "Barbara Cipriani and Arthur Fridman and Claus Bendtsen and Shridar Dharmapuri and Carmela Mennuni and Irene Pak and Giuseppe Mesiti and Guido Forni and Paolo Monaci and Ansu Bagchi and Gennaro Ciliberto and Monica, {Nicola La} and Elisa Scarselli",
year = "2008",
month = "7",
day = "1",
doi = "10.1089/hum.2007.127",
language = "English",
volume = "19",
pages = "670--680",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Therapeutic vaccination halts disease progression in BALB-neuT mice

T2 - The amplitude of elicited immune response is predictive of vaccine efficacy

AU - Cipriani, Barbara

AU - Fridman, Arthur

AU - Bendtsen, Claus

AU - Dharmapuri, Shridar

AU - Mennuni, Carmela

AU - Pak, Irene

AU - Mesiti, Giuseppe

AU - Forni, Guido

AU - Monaci, Paolo

AU - Bagchi, Ansu

AU - Ciliberto, Gennaro

AU - Monica, Nicola La

AU - Scarselli, Elisa

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The aim of this study was to evaluate the efficacy of genetic vaccination with rat ErbB2 antigen in a therapeutic setting for the BALB-neuT mouse model of mammary carcinoma and to establish immunological correlates with vaccine efficacy. To define an early therapeutic setting we performed imaging studies of mouse mammary glands with a high-frequency ultrasound system that allowed the diagnosis of tumor lesions before they become palpable, starting from week 13 after mouse births. An intensive immunization protocol of vaccination was implemented at this stage, consisting of four weekly DNA injections with electroporation followed by two injections of adenovirus carrying the codon usage-optimized cDNA encoding the extracellular-transmembrane domain of rat ErbB2. Immunological parameters were monitored in each individual mouse by analyzing peripheral blood leukocytes. The appearance of the first palpable tumor in vaccinated mice was delayed and there was a statistically significant time gap before additional masses developed, indicating disease stabilization. As a result of the immunization, antibodies and CD8+ T cells to rat ErbB2 were detected and the amplitude of elicited responses correlated with the efficacy of vaccination. Moreover, the vaccination regimen specifically halted the rise in circulating myeloid suppressor cells (MSCs). All three parameters, that is, CD8+ T cells, antibodies to rat ErbB2, and circulating MSCs, measured at the end of vaccination could be used as predictive biomarkers for future tumor development. This study emphasizes the potential of genetic vaccines for the therapeutic treatment of malignancies and suggests possible predictive biomarkers to be further validated in the clinic for the follow-up of vaccinated cancer patients.

AB - The aim of this study was to evaluate the efficacy of genetic vaccination with rat ErbB2 antigen in a therapeutic setting for the BALB-neuT mouse model of mammary carcinoma and to establish immunological correlates with vaccine efficacy. To define an early therapeutic setting we performed imaging studies of mouse mammary glands with a high-frequency ultrasound system that allowed the diagnosis of tumor lesions before they become palpable, starting from week 13 after mouse births. An intensive immunization protocol of vaccination was implemented at this stage, consisting of four weekly DNA injections with electroporation followed by two injections of adenovirus carrying the codon usage-optimized cDNA encoding the extracellular-transmembrane domain of rat ErbB2. Immunological parameters were monitored in each individual mouse by analyzing peripheral blood leukocytes. The appearance of the first palpable tumor in vaccinated mice was delayed and there was a statistically significant time gap before additional masses developed, indicating disease stabilization. As a result of the immunization, antibodies and CD8+ T cells to rat ErbB2 were detected and the amplitude of elicited responses correlated with the efficacy of vaccination. Moreover, the vaccination regimen specifically halted the rise in circulating myeloid suppressor cells (MSCs). All three parameters, that is, CD8+ T cells, antibodies to rat ErbB2, and circulating MSCs, measured at the end of vaccination could be used as predictive biomarkers for future tumor development. This study emphasizes the potential of genetic vaccines for the therapeutic treatment of malignancies and suggests possible predictive biomarkers to be further validated in the clinic for the follow-up of vaccinated cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=47549112087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549112087&partnerID=8YFLogxK

U2 - 10.1089/hum.2007.127

DO - 10.1089/hum.2007.127

M3 - Article

C2 - 18533895

AN - SCOPUS:47549112087

VL - 19

SP - 670

EP - 680

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 7

ER -